USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/28732
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMinchevici, Delia
dc.date.accessioned2024-10-28T12:50:28Z
dc.date.accessioned2024-11-18T21:08:24Z
dc.date.available2024-10-28T12:50:28Z
dc.date.available2024-11-18T21:08:24Z
dc.date.issued2024
dc.identifier.citationMINCHEVICI, Delia. Dapagliflozin as an SGLT2 inhibitor and its effect on the treatment of type 2 diabetes. In: MedEspera: the 10th Intern. Medical Congress for Stud. and Young Doctors, 24-27 April 2024: abstract book. Chișinău, 2024, p. 324. ISBN 978-9975-3544-2-4.en_US
dc.identifier.isbn978-9975-3544-2-4
dc.identifier.urihttps://medespera.md/en/books?page=10
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/28732
dc.descriptionUniversitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldovaen_US
dc.description.abstractIntroduction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a drug class commonly used in the management of type 2 diabetes. Aim of study. Dapagliflozin demonstrated a significant decrease in the occurrence of cardiovascular (CV) death or hospitalization due to heart failure (HHF). Methods and materials. Based on articles about SGLT2 inhibitors from the PubMed platform, we selected the fundamentals of this drug's actions on human metabolism, specifically in patients with type 2 diabetes. Results. The studies consulted from various medical search platforms such as PubMed, Google Scholar, etc., highlight an emphasis on examining the impact of dapagliflozin on body weight. It was observed that this medication assists patients in reducing fat mass, contributing to as much as two-thirds of the overall weight loss, and demonstrates a smaller waist circumference compared to patients who were administered an add-on placebo. Dapagliflozin was orally administered to patients once daily. Conclusion. Real-world studies provided evidence supporting the effectiveness of dapagliflozin in individuals with type 2 diabetes (T2D).en_US
dc.publisherInstituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldovaen_US
dc.relation.ispartofMedEspera: The 10th International Medical Congress for Students and Young Doctors, 24-27 April 2024, Chișinău, Republic of Moldovaen_US
dc.titleDapagliflozin as an SGLT2 inhibitor and its effect on the treatment of type 2 diabetesen_US
dc.typeOtheren_US
Appears in Collections:MedEspera 2024

Files in This Item:
File Description SizeFormat 
MEsp24_324.pdf345.97 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback